Improving Drug Delivery in Cystic Fibrosis Using Exercise

Overview

About this study

This study will explore the effects of delivering a common nebulized drug taken by Cystic fibrosis (CF) patients during exercise.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:  

  • individuals with CF
  • 15-39 years of age
  • BMI <30 kg/m2
  • non-pregnant
  • non-smokers 
  • FEV1>70% predicted
  • be on prescribed albuterol

Exclusion Criteria:

  •  Pulmonary exacerbations within the last 2 months

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Michael Joyner, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions